FDA approves Opdivo/Yervoy combo for melanoma

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA granted accelerated approval for a regimen of Opdivo nivolumab plus Yervoy ipilimumab to treat BRAF V600 wild-type unresectable or metastatic melanoma.

Spokesperson Jaisy Styles told BioCentury four doses of Opdivo plus Yervoy would cost about $141,000. Styles said standard adminstration includes four doses of the combination followed by Opdivo monotherapy until disease progression. Opdivo costs $12,500 per month. ...